Home › Respiratory Distress Syndrome › NCT03859050
Alveolar Macrophage Programming Following Endotoxin Exposure
Who can join
Ages 18 to 50 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: 1. Written, informed consent 2. Age 18-50 Exclusion Criteria: 1. Current or recent illness (past 2 weeks) 2. Presence or prior history of cardiac, pulmonary or systemic disease 3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy 4. American Society of Anesthesiology (ASA) class 2 or greater 5. Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants) 6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine, methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year smoking history 7. Alcohol use disorder or greater than 7 drinks/week for women or greater than 14 drinks/week for men in the past 3 months 8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl 9. Abnormal spirometry or electrocardiogram at time of screening 10. Pregnant (based on urine pregnancy test) or breast feeding
About the study
The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).
What is being tested
- bronchoscopy with intrabronchial administration of lipopolysaccharide (other)
Sponsor: National Jewish Health · Participants: 25 · Started: Mar 18, 2019
Contact the study team
- Kara Mould · Phone: 303-398-1787
Official record on ClinicalTrials.gov — NCT03859050
Locations in the U.S.
| Colorado | National Jewish Health, Denver |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.